alexa The Role of Autonomic Dysregulation from Pathophysiology to Therapeutics of Multiple Sclerosis: A Putative Novel Treatment Target? | OMICS International
ISSN: 2155-9562
Journal of Neurology & Neurophysiology

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The Role of Autonomic Dysregulation from Pathophysiology to Therapeutics of Multiple Sclerosis: A Putative Novel Treatment Target?

Juan Manuel Racosta and Marcelo Kremenchutzky*

Department of Clinical Neurological Sciences, London Health Sciences Centre, Western University, London, ON, Canada

Corresponding Author:
Marcelo Kremenchutzky
339 Windermere Road
P.O. Box 5339 London ON, Canada, N6A 5A5
Tel: 519- 685-8500
Fax: 519-663-3744
E-mail: [email protected]

Received date: February 23, 2014; Accepted dat: May 21, 2014; Published date: May 27, 2014

Citation: Racosta JM, Kremenchutzky M (2014) The Role of Autonomic Dysregulation from Pathophysiology to Therapeutics of Multiple Sclerosis: A Putative Novel Treatment Target?. J Neurol Neurophysiol 5:212. doi:10.4172/2155-9562.1000212

Copyright: © 2014 Racosta JM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Neurology & Neurophysiology


Autonomic Nervous System (ANS) dysfunction (AuD) is a common cause of disability in people living with
Multiple Sclerosis (MS), but clinical manifestations are heterogeneous and therapeutic options are lacking. AuD is
implicated as having a possible role in the regulation of inflammation and neurodegeneration. Hence, treatments
with drugs that affect the ANS may have an impact in the inflammatory and neurodegenerative processes intrinsic to
MS, resulting in an intriguing and potentially significant novel therapeutic consideration. Additionally, just alike
patients with most other chronic diseases, MS patients often are exposed to a broad range of treatments both
disease-specific and due to complications or co-morbidities. Considering them into an integrated context affords the
opportunity to understand and exploit their therapeutic potential.


Multiple sclerosis; Autonomic dysfunction; Immune regulation; Clinical manifestations; Therapeutics

Autonomic Dysfunction in MS: Physiopathology Implications

AuD is a common cause of disability in MS patients, ranging from sphincter (bladder and bowel) dysfunction, to fatigue and cardiovascular autonomic dysfunction (CAD), among others. Both the sympathetic (SNS) and parasympathetic (PNS) nervous systems are frequently, albeit not always simultaneously, compromised [1].

Bladder dysfunction is reported by approximately 75% of people with MS. Filling symptoms (ie failure to store), such as increased frequency, urinary urgency and nocturia, and emptying symptoms, such as intermittency, weak stream and straining at the beginning of urination are the most common manifestations [2]. The lack of ability to inhibit the detrusor muscles controlling urination, leading to neurogenic detrusor overactivity has a high incidence in MS. Bowel disorders are also common in MS, They are present in more than 70% of MS patients and are markedly associated with low quality of life scores [3]. Bowel incontinence, diarrhea and constipation are the commonest manifestations [3], while the most frequent underlying disorders are poor anal sphincter control, gut motility and ano-rectal sensation/coordination [4].

Fatigue is arguably the commonest subjective complain in the MS population, reported in up to 90% of MS patients. It was linked to dysautonomia in some studies, pointing to a sympathetic vasomotor dysfunction with relative cardiovagal integrity [5] and a possible impairment of the sympathovagal balance consisting of a decrease of the vagal function and a normal to low sympathetic activity [6].

The frequency of CAD in the MS population is not well known, since most of the times is asymptomatic [1]. It can be assessed by hemodynamic tests based on heart rate variability (HRV) and blood pressure (BP) analysis. HRV is the physiological phenomenon of variation in the interval between heartbeats related mainly to the hemodynamic changes imposed by breathing and in blood vessel contraction. By measuring each beat-to-beat interval under conditions challenging the autonomic balance, such us sustained muscle contraction and Valsalva maneuver, among others, the amount and amplitude of variation can be calculated, and thus the PNS and SNS activity interpolated [7]. Cardiovascular SNS dysfunction is associated with clinically active MS relapses, while PNS dysfunction correlates with MS progression (relentless worsening independent from relapses) as measured by the expanded disability status score- EDSS [1-4,8,9].

Dysregulation of ANS Mechanisms in MS

SNS and PNS regulate neurotransmitters such as nor-epinephrine (NE), which activates the α- and β- adrenergic receptors (AR, αAR, βAR), and acetylcholine, which activates the muscarinic and nicotinic receptors. ANS and immune regulation have a bi-directional communication. As well as the brain plays a pivotal role in detecting and modulating inflammation through the ANS and the hypothalamic pituitary axis, the immune system dynamically regulates the ANS [9]. Hence, it is arguable that AuD may play a role in the immune regulation in chronic inflammatory diseases. According to the conventional picture in MS, the primary peripheral activation of auto-reactive Th1 lymphocytes precedes the recognition of central nervous system auto-antigens, leading to the release of Th1 (pro-inflammatory) cytokines [10], which in turn produce an activation of the SNS. Then, the SNS exerts a negative feedback to the inflammatory response, triggering a switch to Th2 anti-inflammatory pathways [11,12]. These mechanisms generate a sequential decrease in SNS activity occurring in relapses, and a progressive decline in the noradrenergic axis over time, in parallel with an initially predominant Th1 inflammatory response, switching over the course of the disease to a rather Th2 predominant activity [13]. However this paradigm was challenged by new insights in diverse interrelated ways. First, recent findings implicated novel CD4+ T-cell subsets (TH17, TH9, T regulatory cells –Tregs-) in MS physiopathology [14,15]. Second, despite the role of βAR and lymphocytes endogenous catecholamine’s seems relevant in all the lymphocyte sub-sets, their effects depend on the time of exposure and the degree of cell differentiation and activation. While mediating anti-inflammatory effects in most CD4+ TH cells, they enhance immune responses in specific Treg cell fractions (CD4+CD25 high T cells) [16]. Finally, less is known regarding the specific contribution in MS of the various AR subtypes (α1- α2- β3-ARs), some of them likely to promote inflammatory and neurodegenerative processes [17,18].

PNS dysfunction may also exert influence in immune regulation in MS. The activation of the Vagus nerve culminates in the activation of the nicotinic acetylcholine receptor subunit α7 (α7nAChR), which in turn leads to an anti-inflammatory response through the release of type II cytokines. It was suggested that the dysfunction of the cholinergic anti-inflammatory pathway can exacerbate inflammatory responses in various pathological conditions [19]. However there is limited knowledge regarding its contribution to immune regulation in MS. Despite evidence suggestive of anti-inflammatory signaling via α7nAChR in animal models, the PNS ability to counteract inflammation might be weak [20], and its dysfunction secondary to the underlying pathology of MS, rather than a factor involved in its development.

Therapeutics and Putative Novel Targets for MS Treatment

AR agonists and antagonists are used by their ability to treat a variety of diseases such as hypertension, congestive heart failure and asthma. The pharmacological modulation of adrenergic pathways can also be obtained by use of indirectly acting agents on all the steps involved in noradrenaline and adrenaline synthesis and metabolism. By modifying the central and peripheral NE activity, the inflammatory milieu can also be potentially regulated [1-5]. ß-Blockers (ie bisoprolol, carvedilol, metoprolol) and angiotensin-converting enzyme inhibitors (ie losartan) reduce the NE circulating levels. They showed to decrease the Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure [21]. The expected effect of these drugs varies depending on the stage of the disease, age and gender of the patients (ie more pronounced in females). While these effects may be beneficial by normalizing the initially higher SNS tone in MS, they could also be detrimental by worsening SNS dysfunction in certain late or advanced cases [22]. Tricyclic antidepressant agents (TCA) also affect the sympathetic activation. While they centrally inhibit the sympathetic outflow, in the periphery they block its re-uptake. Therefore, they might reduce central NE, while increasing peripheral NE [13]. Increasing peripheral NE levels through the use of TCA demonstrated sensory, motor and autonomic symptoms improvements in MS patients [23]. Also HMG-CoA reductase inhibitors (statins), widely prescribed as cholesterol-lowering agents, reduce plasma noradrenaline [24]. They were proposed as a treatment option for MS, due to their immune modulatory effects [25], but failed to demonstrate efficacy [26]. Lack of consideration of important aspects, such as pre-treatment with IFN-β, and heterogeneous clinical status among participants are listed as possible causes for the differing clinical outcomes when testing this drug [13]. Manipulation of the GABA pathway by diverse agents also inhibited inflammation in human and murine experimental autoimmune encephalomyelitis (EAE) [27]. The GABA-B receptor agonist baclofen reduces the NA neurotransmission from adrenergic nerve terminals [28], and the release of NE in the cerebral cortex [29]. Also Benzodiazepines reduce NE plasma levels [30] in humans, and it release in the prefrontal cortex of rats [31]. Finally Gabapentin and Pregabalin also inhibited NE release in the brain [27,32]. Despite this, there is still little evidence regarding the involvement of the GABA system in inflammatory mechanisms in MS.

On the contrary, other agents showed ability to increase CNS sympathetic activity. Among them Modafinil up-regulates the CNS NE levels [33] and antidepressants such as MAO inhibitors and SSR inhibitors increase CNS NE levels by inhibiting re-uptake.

More obscure mechanisms are implied with drugs acting on less characterized adrenergic receptors. Clonidine, a centrally-acting agent, which induces activation of CNS α2AR, may promote CNS neurodegenerative processes through the activation of MAP kinases [18].

Clonidine and Tizanidine demonstrated to decrease TNF-α in specific brain regions and inhibiting other Th1 cytokines [34], as α2AR are also capable of inhibiting Th1 cytokines and reducing both peripheral and central NE levels [34].

PNS tone also is modified by direct stimulation of the Vagus nerve or by pharmacological stimulation of both central muscarinic receptors and nicotinic α7nAChR in the periphery. PNS modulation also demonstrated potential for immune regulatory effects. The electrical stimulation of the Vagus nerve attenuated inflammation in a cytokine-dependent rat model of inflammatory disease by inhibiting Th1 cytokines release [35]. The use of an α7nAChR selective agonist (GTS-21) also inhibited the cytokine production in human leukocytes [36]. On the other hand, the decrease of the PNS tone showed opposite effects. In one study based in a mice model of pancreatitis, both vagotomy and the use of a nicotinic receptor antagonist worsen the outcomes, while an α7nAChR agonist strongly decreased the severity of the disease [37]. Similar findings were made in models of lipopolysaccharide-induced inflammatory responses in mouse lung [38] experimental arthritis, ileus and hemorrhagic shock in pre-clinical experimentation [19]. The evidence in experimental models of MS is limited, and studies of parasympathetic modulation in inflammatory CNS diseases in humans are still lacking.

Since recent information provides new perspectives regarding the interaction between the ANS and the immune system, the immunoregulatory effects of other non-pharmacological therapies in MS, such as cooling, biofeedback, acupuncture, hypnosis, meditation and Pavlovian conditioning, should be weighted when considering their effects in the ANS. The beneficial impact of cooling in MS symptoms was demonstrated long time ago, with methods ranging from cold showers, regional cooling devices, cold beverages and cooling garments [39]. Taking into account that the beneficial effect was restricted by detrimental effect on the cardiovascular system, and that it is well known that cooling affects the ANS [40], future research should address this approach considering the impact on the ANS. The effect of biofeedback, acupuncture, hypnosis, meditation and Pavlovian conditioning should be considered under same circumstances.

People living with MS have ANS dysfunction early in the course of the disease and are often treated with drugs affecting the ANS, and potentially the inflammatory and neurodegenerative processes. The complex nature of these interactions remains incompletely understood and deserves further investigation. Treating physicians and patients alike should be more aware of the implications of ANS dysfunction in MS.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 12350
  • [From(publication date):
    May-2014 - Jul 22, 2018]
  • Breakdown by view type
  • HTML page views : 8559
  • PDF downloads : 3791

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version